Nemera’s preservative-free multi-dose eye dropper Novelia approved

Aché partners with Nemera to bring Novelia to Brazilian market

Clilon: Nemera's preservative-free formulation
Aché's Laxime for patients with dry eye syndrome

Nemera is excited to announce that its multi-dose eye dropper Novelia has been approved by ANVISA for the preservative-free formulations Clilon [1] (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat moderately severe pain and inflammation, usually after surgery.

Established for over 54 years, São Paulo-based Aché is one of Brazil’s largest domestic pharmaceutical companies. [2] The Ketorolac products will first be commercialized in a preservative-free multi-dose format in the Brazilian market. These products will be available under prescription only.

Aché is also launching, in parallel, Laxime [3] (Sodium Hyaluronate 0,15%) over the counter (OTC) solution for patients with dry eye syndrome using Novelia.

Aché's Laxime for patients with dry eye syndrome
Aché’s Laxime for patients with dry eye syndrome

The Brazilian market presented a 4% growth ($ PMB IQVIA) in 2020 [4], with dry eye disease experiencing double-digit growth, making it the no.1 category in Brazil within the Ophthalmology market. [5]

Aché partnering with Nemera to improve people’s lives

“The entry of Aché in this segment represents an important reinforcement to the company’s large portfolio. With the mission of enhancing people’s health and longevity, we understand that we also needed to work with ophthalmology to bring the quality and technology of Aché’s products to this medical class. Our goal is not only to offer other options for the medical indication, but also to bring innovation to the Brazilian market in the coming years, and this partnership with Nemera will add great value to our products,” Marcelo Neri, Executive Director of Aché.

“It’s fantastic to see Aché bringing these products to the Brazilian market for the first time and expanding Novelia’s global reach to improve patients’ lives in Latin America. With a growing number of patients suffering from chronic eye conditions, effective drug delivery and patient adherence are increasingly important. Combining the huge advantages of preservative-free formulations to avoid patient irritations with the ease of a multi-dose container system is a win-win, and we are very proud to be partnering with Aché in this launch,” Denise Johnston, Vice President Global Sales at Nemera.

Novelia is a multi-dose closing tip dispensing system that avoids the need for preservatives in the drug and prevents bacterial contamination throughout treatment. A non-return valve system ensures that no contaminated liquid can be re-introduced into the container after the drop has been dispensed. In addition, the patented PureFlow technology (a separate venting system with a silicone membrane) guarantees the intake of air that is free of contamination into the dispenser after drop delivery.

With well over 200 market references worldwide, Novelia is the patient’s preferred choice when it comes to preservative-free multi-dose eyedroppers [6] thanks to its patented blue tip to help in targeting the eye, precise and consistent drop size, and patient-friendly ergonomics, including initiative screw-on cap and optimum squeeze force.

  1. Clilon. Prescribing information. Aché Laboratórios Farmacêuticos S.A.
  2. Annual Report. Aché Laboratórios Farmacêuticos S.A.
  3. Laxime. Prescribing information. Aché Laboratórios Farmacêuticos S.A.
  4. IQVIA. Dec/2020.
  5. Kairos Web Brasil. Available at: March/2021.
  6. Internal Report. Novelia. User study performed for Nemera by an external party to understand the Novelia market opportunities versus competitors”. 76% of patients preferred Novelia over other marketed devices. GfK report, Paris, France, (2015).Note: this article first appeared on

The impact, resilience, and growth of responsible packaging in a wide region are daily chronicled by Packaging South Asia.

A multi-channel B2B publication and digital platform such as Packaging South always aware of the prospect of new beginnings and renewal. Its 16-year-old print monthly, based in New Delhi, India has demonstrated its commitment to progress and growth. The Indian and Asian packaging industries have shown resilience in the face of ongoing challenges over the past three years.

As we present our publishing plan for 2023, India’s real GDP growth for the financial year ending 31 March 2023 will reach 6.3%. Packaging industry growth has exceeded GDP growth even when allowing for inflation in the past three years.

The capacity for flexible film manufacturing in India increased by 33% over the past three years. With orders in place, we expect another 33% capacity addition from 2023 to 2025. Capacities in monocartons, corrugation, aseptic liquid packaging, and labels have grown similarly. The numbers are positive for most of the economies in the region – our platform increasingly reaches and influences these.

Even given the disruptions of supply chains, raw material prices, and the challenge of responsible and sustainable packaging, packaging in all its creative forms and purposes has significant headroom to grow in India and Asia. Our context and coverage engulf the entire packaging supply chain – from concept to shelf and further – to waste collection and recycling. We target brand owners, product managers, raw material suppliers, packaging designers and converters, and recyclers.

In an admittedly fragmented and textured terrain, this is the right time to plan your participation and marketing support communication – in our impactful and highly targeted business platform. Tell us what you need. Speak and write to our editorial and advertising teams! For advertisement , for editorial and for subscriptions

– Naresh Khanna

Subscribe Now


Please enter your comment!
Please enter your name here